MwanzoINRLF • OTCMKTS
add
Valneva SE
Bei iliyotangulia
$ 3.25
Bei za mwaka
$ 1.88 - $ 4.14
Thamani ya kampuni katika soko
521.85M USD
Wastani wa hisa zilizouzwa
400.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Habari za soko
The Motley Fool
saa 7 zilizopita
1 Magnificent S&P 500 Dividend Stock Down 24% to Buy and Hold Forever
1.42%
1.03%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 49.23M | 50.31% |
Matumizi ya uendeshaji wa biashara | 17.20M | 124.31% |
Mapato halisi | -9.23M | -115.67% |
Kiwango cha faida halisi | -18.75 | -110.42% |
Mapato kwa kila hisa | -0.14 | -115.41% |
EBITDA | -2.28M | -103.21% |
Asilimia ya kodi ya mapato | -19.00% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 152.99M | -13.39% |
Jumla ya mali | 482.24M | -4.09% |
Jumla ya dhima | 306.99M | -2.11% |
Jumla ya hisa | 175.25M | — |
hisa zilizosalia | 153.87M | — |
Uwiano wa bei na thamani | 2.85 | — |
Faida inayotokana na mali | -3.03% | — |
Faida inayotokana mtaji | -3.80% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -9.23M | -115.67% |
Pesa kutokana na shughuli | -8.15M | 71.34% |
Pesa kutokana na uwekezaji | elfu -961.00 | -101.11% |
Pesa kutokana na ufadhili | -5.58M | 25.14% |
Mabadiliko halisi ya pesa taslimu | -15.28M | -130.22% |
Mtiririko huru wa pesa | -19.68M | -198.73% |
Kuhusu
Valneva SE is a speciality vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company current market three proprietary travel vaccines.
Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats.
Valneva has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2013
Tovuti
Wafanyakazi
713
